# Smart Nuclide

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/smart-nuclide

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.smartnucl.com
- Total disclosed funding: $30M
- Latest round: Series C (Jul 6, 2021)
- Investors on record: 10

## About

Based in China and established in 2015, Smart Nuclide is a clinical-stage biopharmaceutical company that engages in the research and development of biological drug products for molecular nuclear oncology. The company’s FIH radiotherapeutic drug has received PCC (preclinical candidate compounds) certificate. It has established a Class B qualified radiopharmaceutical GMP workshop, and a branch office in Shanghai. The company has cooperated with Shanxi Medical University, Jiangsu Institute of Atomic Medicine, Shandong Cancer Hospital and other universities, research institutes and hospitals. In April 2024, Smart Nuclide raised approximately CNY 100 million in series C+ funding.

Smart Nuclide provides products including recombinant human thyrotropin, tumor diagnostic radiographic drugs, and tumor therapeutic radiopharmaceuticals based on its single-domain antibody development platform and radionuclide coupling labeling platform. The company has deployed more than 10 innovative nuclide diagnostic and treatment product pipelines, and its main product is human thyroid-stimulating hormone.

The company generates revenue by developing and selling products including recombinant human thyrotropin, tumor diagnostic radiographic drugs, and tumor therapeutic radiopharmaceuticals.

Smart Nuclide will accelerate the launch of its human thyrotropin injection, clinical trials of innovative radioactive diagnostic drugs such as SNA002, and IND (Investigational New Drug) advancement of new target therapeutic nuclear drugs such as SNA014 and SNA025.

## Funding rounds

- Series C, Jul 6, 2021, $15M — Ciit Asset Management, Qirong Venture Capital, Tasly Capital, ABC International Capital
- Series B, Apr 24, 2020, $14M — Jiuyo Capital, Shanghai Ruihe Asset Management
- Series A, Nov 12, 2018 — Zhuhai Longmen Capital Management
- Series A, Feb 2, 2018 — Kington Capital, Watson Capital
- Angel, Mar 21, 2016 — Bohe Angel Fund

## Investors

- Bohe Angel Fund — Angel
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series A
- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series B
- Shanghai Ruihe Asset Management — Series B
- Ciit Asset Management (https://capitalatlas.ai/funds/ciit-asset-management) — Series C
- Qirong Venture Capital (https://capitalatlas.ai/funds/qirong-venture-capital) — Series C
- Tasly Capital — Series C
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series C